Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.30 --0%
Revenue Growth %: +37.8%
Financial Fact:
Other income: 348K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Other income: 348K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
